Last reviewed · How we verify
CQ coadministered with PQ
CQ (chloroquine) and PQ (primaquine) work together as antimalarial agents that disrupt parasite metabolism and eliminate both blood and tissue stages of Plasmodium infection.
CQ (chloroquine) and PQ (primaquine) work together as antimalarial agents that disrupt parasite metabolism and eliminate both blood and tissue stages of Plasmodium infection. Used for Malaria (mixed species or P. vivax/P. ovale with relapse prevention), Uncomplicated malaria treatment and radical cure.
At a glance
| Generic name | CQ coadministered with PQ |
|---|---|
| Also known as | Standard treatment with potential synergy |
| Sponsor | Fundação de Medicina Tropical Dr. Heitor Vieira Dourado |
| Drug class | Antimalarial combination |
| Target | Plasmodium heme detoxification pathway; hypnozoite elimination |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | Phase 3 |
Mechanism of action
Chloroquine inhibits heme polymerization in the parasite's digestive vacuole, killing asexual blood stages of malaria parasites. Primaquine acts on hypnozoites in the liver, preventing relapse by eliminating the dormant tissue stages, particularly in P. vivax and P. ovale infections. The combination provides comprehensive parasite clearance across all life cycle stages.
Approved indications
- Malaria (mixed species or P. vivax/P. ovale with relapse prevention)
- Uncomplicated malaria treatment and radical cure
Common side effects
- Gastrointestinal disturbance (nausea, vomiting, abdominal pain)
- Hemolysis (in G6PD-deficient patients from primaquine)
- Headache
- Pruritus
- Dizziness
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: